Indivisible Partners Makes New $484,000 Investment in Anika Therapeutics Inc. $ANIK

Indivisible Partners purchased a new position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 50,402 shares of the biotechnology company’s stock, valued at approximately $484,000.

Other large investors also recently bought and sold shares of the company. CWM LLC increased its holdings in Anika Therapeutics by 526.6% during the 3rd quarter. CWM LLC now owns 7,457 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 6,267 shares during the period. Quarry LP purchased a new stake in Anika Therapeutics during the 3rd quarter worth about $71,000. Occudo Quantitative Strategies LP purchased a new stake in Anika Therapeutics during the 3rd quarter worth about $95,000. Williams & Novak LLC purchased a new stake in Anika Therapeutics during the 3rd quarter worth about $102,000. Finally, Tudor Investment Corp ET AL purchased a new stake in Anika Therapeutics during the 3rd quarter worth about $107,000. Hedge funds and other institutional investors own 91.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ANIK shares. Wall Street Zen downgraded Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Barrington Research upped their price target on Anika Therapeutics from $16.00 to $17.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $17.00.

Insider Activity

In other Anika Therapeutics news, CEO Stephen D. Griffin acquired 12,200 shares of the stock in a transaction dated Thursday, April 30th. The stock was acquired at an average cost of $12.29 per share, with a total value of $149,938.00. Following the transaction, the chief executive officer owned 36,163 shares in the company, valued at $444,443.27. The trade was a 50.91% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John B. Henneman III acquired 5,000 shares of the stock in a transaction dated Friday, May 1st. The shares were acquired at an average cost of $14.66 per share, with a total value of $73,300.00. Following the completion of the transaction, the director owned 54,871 shares in the company, valued at approximately $804,408.86. This represents a 10.03% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 9.64% of the company’s stock.

Anika Therapeutics Stock Performance

NASDAQ:ANIK opened at $15.14 on Friday. The stock has a 50-day simple moving average of $14.57 and a 200-day simple moving average of $11.44. The stock has a market cap of $201.51 million, a P/E ratio of -19.16 and a beta of 0.16. Anika Therapeutics Inc. has a 1 year low of $7.87 and a 1 year high of $16.24.

Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.34. The business had revenue of $29.61 million during the quarter, compared to analysts’ expectations of $28.14 million. Anika Therapeutics had a negative return on equity of 5.90% and a negative net margin of 9.52%. On average, equities research analysts predict that Anika Therapeutics Inc. will post -0.74 EPS for the current year.

About Anika Therapeutics

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.